Loading…
Serina Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in SER.
▼ -92.8% over 5Y.
today you would have $62.26▼ -93.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.91 | $5.01 | $13.75 | $19.71 | |
| P/E | — | — | — | 22.0x | — |
| P/S | — | — | — | 38.6x | 331.7x |
| P/B | — | — | 73.6x | — | — |
| EPS | -$1.91 | -$1.51 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TLPHTalphera Inc | $1.20 | — | 3.3x | — | -143.36% | $62.29M |
| BSEMBioStem Technologies, Inc. | $3.53 | 4.0x | 2.3x | — | -74.74% | $62.95M |
| MYOMyomo Inc | $1.60 | — | 10.9x | — | -123.76% | $63.37M |
| HYPDHyperion Defi Inc | $3.92 |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Company description provided by Yahoo Finance.
| $0.63 |
| -$1.23 |
| Profit margin | — | — | — | 175.63% | -536.42% |
| ROE | — | — | -1738.07% | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.6x |
| — |
| 9.55% |
| $60.84M |
| IMAImageneBio, Inc. | $5.34 | — | 0.4x | — | -82.68% | $60.74M |
| BOLDBoundless Bio, Inc. | $2.83 | — | 1.0x | — | -67.86% | $64.38M |